menu
    • menu

    Company profile for Reven Pharmaceuticals

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Reven Pharmaceuticals is a privately-held clinical-stage biopharmaceutical company founded in 1999. In 2008, Reven initiated compassionate care use with RJX technology in South Africa for patients with limited to no therapeutic options. This opportunity to aid patients also greatly improved Reven’s understanding of the product, enhancing knowledge in areas of dosing, product stabilization, patient healing trajectories, and o...
    Reven Pharmaceuticals is a privately-held clinical-stage biopharmaceutical company founded in 1999. In 2008, Reven initiated compassionate care use with RJX technology in South Africa for patients with limited to no therapeutic options. This opportunity to aid patients also greatly improved Reven’s understanding of the product, enhancing knowledge in areas of dosing, product stabilization, patient healing trajectories, and outcome analysis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Reven PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2921 W. 120th Ave Suite 220 Westminster, CO 80234
    Telephone
    Telephone
    1-720-618-0658
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://reven.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/revenpharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/revenpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Reven’s anti-sepsis drug provides rapid recovery in Covid-19 trial
    Reven’s anti-sepsis drug provides rapid recovery in Covid-19 trial

    27 Sep 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/reven-anti-sepsis-drug/

    CLINICALTRIALSARENA
    27 Sep 2021
    Share Share
    Reven’s Co-Founder Michael Volk Appears on Cheddar News
    Reven’s Co-Founder Michael Volk Appears on Cheddar News

    09 Jul 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210709005449/en

    BUSINESSWIRE
    09 Jul 2021
    Share Share
    Reven Pharma Reports a Promising 2nd Generation Formulation of Rejuveinix (RJX)
    Reven Pharma Reports a Promising 2nd Generation Formulation of Rejuveinix (RJX)

    18 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210618005090/en/Reven-Pharmaceuticals-Reports-a-Promising-Second-Generation-Formulation-of-Its-Lead-Anti-sepsis-Drug-Candidate-Rejuveinix-RJX

    BUSINESSWIRE
    18 Jun 2021
    Share Share
    Reven Reports a Promising Second Generation Formulation of Rejuveinix
    Reven Reports a Promising Second Generation Formulation of Rejuveinix

    18 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210618005090/en

    BUSINESSWIRE
    18 Jun 2021
    Share Share
    Reven Reports Positive Results Regarding the Safety and Preclinical Efficacy
    Reven Reports Positive Results Regarding the Safety and Preclinical Efficacy

    11 Nov 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/reven-pharmaceuticals-reports-positive-results-regarding-the-clinical-safety-and-preclinical-efficacy-of-its-covid-19-drug-candidate-rejuveinix-rjx-/

    BIOSPACE
    11 Nov 2020
    Share Share
    Reven Wins FDA Approval of Its IND Application for Rejuveinix (RJX)
    Reven Wins FDA Approval of Its IND Application for Rejuveinix (RJX)

    23 Oct 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/reven-pharmaceuticals-wins-fda-approval-of-its-ind-application-for-treatment-of-covid-19-with-rejuveinix-rjx-/

    BIOSPACE
    23 Oct 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search